Statin hyporesponders may have blocked arteries
the ONA take:
According to a new study published in the journal Arteriosclerosis, Thrombosis and Vascular Biology, researchers have found that if a patient's low density lipoprotein (LDL), or "bad cholesterol," stays the same or increases after taking statin medications, the patient may have more blocked arteries compared with patients whose LDL decreases.
For the study, researchers from the South Australian Health & Medical Research Institute in Adelaide, Australia, analyzed data from seven studies that included 647 patients diagnosed with coronary artery disease who took statin medications, such as simvastatin, atorvastatin, and rosuvastatin, to help decrease LDL.
In all of the studies, patients' arteries were studied with ultrasound before and after statin treatment. Results showed that the 20% of patients considered statin hyporesponders (their LDL cholesterol levels decreased a little, stayed the same, or increased) experienced more plaque accumulation in their arteries compared with patients who responded to statin therapy.
Researchers found among the statin hyporesponders, 79% were men with an average age of 56 years, while 66% were men with an average age of 58 years among statin responders.
Low density lipoprotein, or "bad cholesterol," stays the same or increases after taking statin medications.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|